VALBIOTIS news, videos and press releases - Page 3
For more news please use our advanced search feature.
VALBIOTIS - More news...
VALBIOTIS - More news...
- Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan
- Valbiotis Announces Positive Preclinical Results for TOTUM•070 in Hypercholesterolemia, Selected and Presented at the American Heart Association (AHA) Annual Meeting
- Valbiotis Reviews Its Activities and Publishes Its Financial Report for the First Half of 2021
- Valbiotis Consolidates Its Development of Innovative Natural Health Solutions by Integrating the Exploration of Microalgae Produced in New Caledonia, Through an Exclusive Agreement With ADECAL-Technopole and IFREMER
- Valbiotis Releases its Letter to Shareholders for 2021
- Valbiotis Announces the Completion of Recruitment for the Phase II HEART Clinical Study Conducted With TOTUM•070 in Hypercholesterolemia, a Risk Factor for Cardiovascular Disease
- Valbiotis Announces the Implementation of the TOTUM•63 Mode of Action Clinical Study by INAF1 at Laval University in Quebec City, in Partnership With Nestlé Health Science
- Valbiotis Appoints Sébastien Bessy, International Expert in Consumer Healthcare, as Chief Operating Marketing and Business Officer
- Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action
- Valbiotis Granted a €1.25 Million Innovation Support Loan by Bpifrance
- Valbiotis Obtains Patent for Its Active Substance TOTUM•63 in China, a Large Potential Market for the Prevention of Type 2 Diabetes and Metabolic Diseases
- Valbiotis' Combined General Meeting on May 27, 2021 Will Exceptionally Be Held Behind Closed Doors
- Valbiotis: Largely Successful Capital Increase Through a Private Placement Totaling 15 Million Euros
- Valbiotis Launches a Capital Increase Through a Private Placement
- Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH-ISH Joint Meeting
- VALBIOTIS Obtains ISO 9001 Certification for Its Activities in "Design, Development and Production Control of Solutions for Preventing and Combating Metabolic and Cardiovascular Diseases"
- VALBIOTIS Releases Its 2020 Annual Results
- VALBIOTIS: 2021 Financial Communication Calendar
- VALBIOTIS Selected to Present TOTUM-854’s Results on Arterial Hypertension at the Annual Meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) in April 2021
- VALBIOTIS Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021
- VALBIOTIS Authorized to Launch HEART, the Phase II Multi-center Clinical Study With TOTUM-070, for the Reduction of Blood LDL-cholesterol Levels
- VALBIOTIS Announces Its Participation in the 39th J.P. Morgan Healthcare Annual Conference as well as in H.C. Wainwright BioConnect from January 11-14, 2021, in Virtual Format
- VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART
- VALBIOTIS Integrates The EnterNext© PEA-PME 150 Index From Euronext Paris
- VALBIOTIS Publishes Its 2020 Half-Year Results and Provides an Update on Its Global Strategic Partnership with Nestlé Health Science, its strong Financial Visibility and the Promising Advances in Its Pipeline
- VALBIOTIS Selected to Present 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD)
- VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia
- VALBIOTIS Announces a Cash Position of €10.9M at 30 June 2020
- VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors
- VALBIOTIS: Authorization to Launch the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63, to Reduce Type 2 Diabetes Risk Factors
